Navigating immuno-oncology

Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, has announced new data that further characterises and enhances the immunocompetent models included in their large-scale immunotherapy screening platform, MuScreen.

MuScreen is a large-scale, staggered screening platform that interrogates a panel of commonly used syngeneic tumour models to advance investigations of immuno-oncology agents. “CrownBio is a leading provider of innovative solutions for the discovery and development of immunotherapies,” said Dr Henry Li, CrownBio's Senior Vice President of Scientific Research and Innovation. “We remain committed to further expanding and characterising models within the unique MuScreen platform to help our clients navigate their novel immuno-oncology development programmes more efficiently.”